US FDA approves J&J's combination therapy for type of lung cancer

Send a link to a friend  Share

[August 20, 2024]  (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination therapy for patients with a type of non-small cell lung cancer.

(Reporting by Bhanvi Satija in Bengaluru and Sneha S K; Editing by Shilpi Majumdar)

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

[to top of second column]

US FDA approves J&J's combination therapy for type of lung cancer

 

 

Back to top